...
首页> 外文期刊>The journal of immunology >Tumor-Infiltrating Dendritic Cells Are Potent Antigen-Presenting Cells Able to Activate T Cells and Mediate Tumor Rejection
【24h】

Tumor-Infiltrating Dendritic Cells Are Potent Antigen-Presenting Cells Able to Activate T Cells and Mediate Tumor Rejection

机译:肿瘤浸润树突状细胞是有力的抗原呈递细胞,能够激活T细胞并介导肿瘤排斥

获取原文

摘要

Dendritic cells (DC) are potent inducers of immune responses. DC have been shown to infiltrate tumors, but very little is known about the functional status of these naturally occurring tumor-infiltrating DC (TIDC). In this study, the status and function of TIDC from several types of mouse melanoma were investigated in detail. CD11c+/MHC II+ cells, consistent with a DC phenotype, were found in all of transplantable or spontaneous melanomas studied. These TIDC were predominantly myeloid (CD11c+/CD8α?/B220?) in nature with small numbers of plasmacytoid (CD11c+/B220+). TIDC had an intermediate maturation phenotype with some expression of costimulatory molecules and the capacity to take up particles. Upon culture overnight ex vivo, the TIDC markedly up-regulated the expression of costimulatory molecules and also increased IL-12 production. Importantly, such ex vivo-matured TIDC pulsed with OVA were able to migrate to lymph nodes, to activate naive OVA-specific CD4+ and CD8+ T cells, and to confer protection against a challenge with OVA-expressing tumor cells. In conclusion, melanomas are infiltrated by functional DC that can act as fully competent APC. These APC have the potential to be manipulated and may therefore represent a promising target for cancer immunotherapy.
机译:树突状细胞(DC)是免疫反应的有效诱导剂。已经证明DC可以浸润肿瘤,但是对于这些天然存在的肿瘤浸润DC(TIDC)的功能状态知之甚少。在这项研究中,详细研究了几种类型的小鼠黑素瘤TIDC的地位和功能。在所有研究的可移植或自发性黑色素瘤中均发现了与DC表型一致的CD11c + / MHC II +细胞。这些TIDC本质上主要是髓样(CD11c + /CD8αβ/B220β)和少量浆细胞样(CD11c + / B220 +)。 TIDC具有中间成熟表型,具有一定的共刺激分子表达和吸收颗粒的能力。在离体培养过夜后,TIDC明显上调了共刺激分子的表达,并增加了IL-12的产生。重要的是,这种用OVA脉冲离体成熟的TIDC能够迁移到淋巴结,激活原始的OVA特异性CD4 +和CD8 + T细胞,并赋予针对表达OVA的肿瘤细胞发起攻击的保护。总之,黑色素瘤被功能性DC浸润,可以作为完全有能力的APC。这些APC具有被操纵的潜力,因此可能代表癌症免疫疗法的有希望的靶标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号